【以色列初创公司Nucleai完成1400万美元B+轮融资，引领AI在生物标志物分析中的新突破】
以色列AI空间生物标志物分析初创公司Nucleai近日宣布，成功获得1400万美元的B+轮融资，此轮融资由知名投资机构M Ventures领投。Nucleai的现有投资者，包括Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel和Grove Ventures等也积极参与了本次投资。
Nucleai专注于利用人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以期预测疾病治疗的效果。这一创新方法在生物医学研究领域具有重大意义，为精准医疗和疾病诊断提供了新的可能。
据CTech报道，Nucleai的这项技术能够帮助科学家们更准确地理解疾病在细胞水平上的行为，从而为开发更有效的治疗策略提供关键信息。此次融资将进一步推动Nucleai的研发进程，加速其在病理学和临床研究中的应用。
Nucleai的B+轮融资成功，不仅彰显了投资者对其技术潜力的信任，也标志着AI在生物医学领域中的应用正不断深化，有望在未来为医疗健康行业带来颠覆性的变革。
英语如下：
**News Title:** “AI Biomarker Analysis Company Nucleai Secures $14M in B+ Round, Pioneering a New Era in Pathological Image Intelligence”
**Keywords:** AI bioanalysis, Nucleai funding,病理 image recognition
**News Content:** _Israeli startup Nucleai completes $14 million B+ funding round, leading AI advancements in biomarker analysis_
Israeli AI startup Nucleai, specializing in spatial biomarker analysis, recently announced it has successfully raised $14 million in a B+ funding round led by prominent investor M Ventures. The round also saw active participation from Nucleai’s existing investors, including Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures.
Nucleai focuses on leveraging artificial intelligence and machine learning technologies to perform in-depth analysis of pathological images and spatial data at the cellular and tissue levels, aiming to predict the outcome of disease treatments. This innovative approach holds significant implications in biomedical research, offering new possibilities for precision medicine and diagnostic accuracy.
According to CTech, Nucleai’s technology enables scientists to better understand disease behavior at a cellular level, providing crucial insights for the development of more effective therapeutic strategies. The fresh funding will propel Nucleai’s research and development, accelerating its application in pathology and clinical studies.
Nucleai’s successful B+ round not only underscores investors’ confidence in its technological potential but also signifies the growing depth of AI integration in the biomedical field. This development is poised to bring transformative changes to the healthcare industry in the future.
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1